Navigation Links
Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula

CHERRY HILL, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu(TM) has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu. The Reme-Flu(TM) formula consists of a two-part protocol. Part one contains clinically researched ingredients that have been shown to lessen both the duration and severity of flu symptoms. Part two consists of homeopathic sublingual tinctures that are focused on helping lessen respiratory symptoms commonly associated with the flu. This uniquely designed product's two-part protocol flu remedy provides a comprehensive and effective means for safely treating symptoms of the flu.

Homeopathy has a long and successful track record for helping to safely prevent and treat flu symptoms, including typical aches and pains that accompany the flu. During the last flu pandemic, occurring in 1918, homeopathy's performance was outstanding. According to a May, 1921 article in the Journal of the American Institute of Homeopathy, Dr. T A McCann stated that of 26,000 cases of the Spanish Flu treated allopathically (conventional treatment), the mortality rate was 28.2%. Conversely, of the 26,000 cases of Spanish Flu treated with homeopathy, the mortality rate was 1.05%. At the same time, statistics collected from Connecticut of over 6,600 cases of Spanish Flu treated homeopathically showed a mortality rate of less than 1%. During the same pandemic, the Homeopathic Medical Society reported the same impressive statistical findings for 1,500 cases treated with homeopathic remedies in the Washington D.C. area.

About Legacy Biotechnologies, Inc.

Legacy Biotechnologies, Inc. is an independent, privately owned firm specializing in research and development of nutraceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed both on a national basis and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from Please visit for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777

SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
2. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
3. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
4. Nuvilex, Inc. Announces Business Update Conference Call
5. Nuvilex, Inc. Announces Monthly Investor Conference Call
6. Nuvilex, Inc. Announces Investor Conference Call and Open House
7. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
8. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
9. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
10., Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
11. JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)... -- The American Academy of Pediatrics (AAP), American Congress ... of Dimes cheered today,s signature into law of ... 2015 (S.799), which takes much-needed strides to ... drugs, such as opioids, and to improve their ... have worked together leading advocacy efforts for its ...
Breaking Medicine Technology: